Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety, Tolerability and Performance of the NucleoCapture Device in the Reduction of Circulating CfDNA/NETs in Subjects with Sepsis
Sponsor: Santersus AG
Summary
This is a prospective, multinational, multicentre, randomised, parallel-group, open-label study to assess the safety, tolerability and performance of the NucleoCapture extracorporeal apheresis device in the reduction of circulating cell-free DNA (cfDNA)/Neutrophil Extracellular Traps (NETs) in sepsis patients.
Official title: Safety, Tolerability and Performance of the NucleoCapture Extracorporeal Therapeutic Apheresis Device in the Reduction of Circulating CfDNA/NETs in Subjects with Sepsis
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
73
Start Date
2025-07-01
Completion Date
2027-05-28
Last Updated
2024-11-29
Healthy Volunteers
No
Conditions
Interventions
NucleoCapture device
100ml NucleoCapture selective DNA adsorber
Locations (9)
University of Bonn
Bonn, Germany
Technical University Dresden
Dresden, Germany
Hannover Medical School
Hannover, Germany
University of Zurich
Zurich, Switzerland
Queen Elizabeth Hospital Birmingham
Birmingham, United Kingdom
Royal Infirmary of Edinburgh
Edinburgh, United Kingdom
Liverpool University Hospital
Liverpool, United Kingdom
Guy's and St Thomas' Hospital
London, United Kingdom
University College London
London, United Kingdom